Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P54803

UPID:
GALC_HUMAN

ALTERNATIVE NAMES:
Galactocerebroside beta-galactosidase; Galactosylceramidase; Galactosylceramide beta-galactosidase

ALTERNATIVE UPACC:
P54803; B4DKE8; B4DYN1; B4DZJ8; B7Z7Z2; J3KN25; J3KPP8; Q8J030

BACKGROUND:
Galactocerebrosidase, essential for the hydrolysis of galactose ester bonds in glycolipids such as galactosylceramide, is a key enzyme in maintaining the integrity of myelin, kidney, and intestinal and colon epithelial cells. Its alternative names include Galactocerebroside beta-galactosidase, Galactosylceramidase, and Galactosylceramide beta-galactosidase.

THERAPEUTIC SIGNIFICANCE:
Impairments in Galactocerebrosidase function lead to Krabbe disease, characterized by a spectrum of neurological symptoms. Targeting Galactocerebrosidase for therapeutic intervention could significantly impact the treatment of Krabbe disease, offering hope for patients and families affected by this challenging condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.